Literature DB >> 28511398

Undifferentiated Uterine Sarcoma: An Uncommon Case Report.

Madhumita Mukhopadhyay1, Chhanda Das2, Tamanna Parvin3, Keya Basu4.   

Abstract

Endometrial Stromal Sarcomas (ESS) are rare uterine malignancy of mesodermal origin. A 65-year-old female presented with postmenopausal bleeding in the Department of Gynaecology in our hospital. Computed Topography (CT) revealed an enlarged uterus with areas of low attenuation. On gross appearance endometrial cavity was distorted with an irregular friable necrotic mass. Histopathologically, it was diagnosed as undifferentiated uterine sarcoma. Rhabdoid, osteoid and cartilaginous differentiation were found along with osteoclast like giant cells. Immunohistochemistry was strongly positive for CD10.

Entities:  

Keywords:  CD10; Postmenopausal bleeding; Uterine malignancy

Year:  2017        PMID： 28511398      PMCID： PMC5427324          DOI： 10.7860/JCDR/2017/24924.9370

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN： 0973-709X


  10 in total

1.  Gastrointestinal stromal tumors metastatic to the ovary: a report of five cases.

Authors:  Julie A Irving; Melinda F Lerwill; Robert H Young
Journal:  Am J Surg Pathol       Date:  2005-07       Impact factor: 6.394

Review 2.  Endometrial stromal tumors: an update on a group of tumors with a protean phenotype.

Authors:  E Oliva; P B Clement; R H Young
Journal:  Adv Anat Pathol       Date:  2000-09       Impact factor: 3.875

3.  Allelic imbalances in endometrial stromal neoplasms: frequent genetic alterations in the nontumorous normal-appearing endometrial and myometrial tissues.

Authors:  Farid Moinfar; Marie-Luise Kremser; Yan Gao Man; Kurt Zatloukal; Fattaneh A Tavassoli; Helmut Denk
Journal:  Gynecol Oncol       Date:  2004-12       Impact factor: 5.482

4.  High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes.

Authors:  Edward J Tanner; Karuna Garg; Mario M Leitao; Robert A Soslow; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2012-06-26       Impact factor: 5.482

5.  Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients.

Authors:  Vera M Abeler; Odd Røyne; Steinar Thoresen; Håvard E Danielsen; Jahn M Nesland; Gunnar B Kristensen
Journal:  Histopathology       Date:  2009-02       Impact factor: 5.087

6.  A malignant gastrointestinal stromal tumor with osteoclast-like giant cells.

Authors:  Kai Man Leung; Shun Wong; Tat Chong Chow; Kam Cheong Lee
Journal:  Arch Pathol Lab Med       Date:  2002-08       Impact factor: 5.534

7.  Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases.

Authors:  Shuichi Kurihara; Yoshinao Oda; Yoshihiro Ohishi; Atsuko Iwasa; Tomonari Takahira; Eisuke Kaneki; Hiroaki Kobayashi; Norio Wake; Masazumi Tsuneyoshi
Journal:  Am J Surg Pathol       Date:  2008-08       Impact factor: 6.394

Review 8.  Uterine sarcomas: a review.

Authors:  Emanuela D'Angelo; Jaime Prat
Journal:  Gynecol Oncol       Date:  2009-10-23       Impact factor: 5.482

9.  Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases.

Authors:  Robert A Soslow; Asya Ali; Esther Oliva
Journal:  Am J Surg Pathol       Date:  2008-07       Impact factor: 6.394

10.  Endometrial carcinosarcoma with osteoclast-like giant cells.

Authors:  F Amant; I Vandenput; T Van Gorp; I Vergote; Ph Moerman
Journal:  Eur J Gynaecol Oncol       Date:  2006       Impact factor: 0.196
  10 in total
  2 in total

1.  Basaloid squamous cell carcinoma of the uterine cervix coexisting with undifferentiated sarcoma.

Authors:  Magdalena Lemm; Łukasz Słowik; Bartosz Cichoń; Michał Poński; Łukasz Szwaczka; Igor Bakon; Andrzej Witek
Journal:  Prz Menopauzalny       Date:  2021-01-07

2.  Metastatic low-grade endometrial stromal sarcoma with sex cord and smooth muscle differentiation: A case report.

Authors:  Qi Zhu; Yan-Qin Sun; Xiao-Qing Di; Bing Huang; Jian Huang
Journal:  World J Clin Cases       Date:  2019-01-26       Impact factor: 1.337
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.